Physician profile
John P Baron
NPI 1861471591
$6,038.93
in general payments reported to CMS, 2019-2025
24 companies · $397 in 2025
The $397 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.59 · 2021: $56.34 · 2022: $567 · 2023: $4,263 · 2024: $744 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,037 · Food and Beverage: $2,347 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,037.00 |
| Food and Beverage | $2,346.86 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $3,575.39 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $809.59 | 2022-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $240.57 | 2022-2023 | Veltassa |
| Calliditas Therapeutics US INC. | $197.34 | 2022-2023 | Tarpeyo |
| Fresenius USA Marketing, INC. | $123.85 | 2023-2025 | Velphoro, Velphoro |
| Baxter Healthcare | $114.31 | 2021-2022 | |
| Ardelyx, INC. | $113.14 | 2023-2024 | Ibsrela |
| Amgen INC. | $106.60 | 2022-2025 | Tavneos |
| Otsuka America Pharmaceutical, INC. | $94.02 | 2022-2025 | Jynarque |
| Novo Nordisk INC | $78.99 | 2022-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $77.78 | 2022-2023 | Benlysta |
| Novartis Pharmaceuticals Corporation | $76.52 | 2024 | |
| Horizon Therapeutics Plc | $65.76 | 2023 | Krystexxa |
| Travere Therapeutics, INC. | $65.70 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.09 | 2023-2024 | Jardiance |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $53.23 | 2022-2024 | Terlivaz, Acthar |
| Erbe USA INC | $40.00 | 2025 | Cryo2 |
| Straumann USA LLC | $37.79 | 2021 | |
| Dexcom, INC. | $22.92 | 2024 | Dexcom G6 Transmitter |
| Aurinia Pharma U.S., INC. | $20.44 | 2023 | Lupkynis |
| Chiesi USA, INC. | $20.21 | 2025 | Kengreal |
| Lilly USA, LLC | $20.17 | 2024 | Jardiance |
| Epi Health, LLC | $13.93 | 2022 | |
| Daiichi Sankyo INC. | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Baron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.